OOIR: Observatory of International Research

Papers

(The H4-Index of Allergy is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Issue Information	759
Issue Information	365
Issue Information	330
Correspondence to “Basophil activation test as predictor of severity and threshold of allergic reactions to egg”	286
The Presence and Pathogenic Roles of M(IL‐33 + IL‐2) Macrophages in Allergic Airway Inflammation	243
Type 2 memory B cells: The repository of allergic memory?	178
	168
Algorithms in allergy: An algorithm for alpha‐Gal syndrome diagnosis and treatment, 2024 update	166
Prospective (e‐diary) vs retrospective (ARIA) measures of severity in allergic rhinoconjunctivitis: An observational compatibility study	158
Impact of COVID‐19 on care‐seeking patterns for hay fever in Japan: A retrospective claims database cohort study	156
Longitudinal analyses of development of the immune system during the first five years of life in relation to lifestyle	154
Clinical applicability of the urticaria control test in patients with chronic urticaria: Further evidence from 622 adult and pediatric patients with different disease subtypes	118
Correspondence to “Allergic bronchopulmonary aspergillosis with atopic, nonatopic, and sans asthma—Factor analysis”	112
Next generation health guidelines: The role of real‐life data in evidence‐based medicine	110
In memoriam: Lawrence M. Lichtenstein (1934–2022)	110
Vaccine based on folded receptor binding domain‐PreS fusion protein with potential to induce sterilizing immunity to SARS‐CoV‐2 variants	109
Angiomotin and angiostatin as asthma biomarkers: Implications for the regulation of airway remodeling and inflammation	107
MUC1 deficiency induces the nasal epithelial barrier dysfunction via RBFOX3 shortage augment ubiquitin–proteasomal degradation in allergic rhinitis pathogenesis	102
In vivo and ex vivo inflammatory responses of the esophageal mucosa to food challenge in adults with eosinophilic esophagitis	99
Pre‐existing inflammation reduces the response to contact allergens in Tmem79‐deficient mice	98
Autoantibodies in COVID‐19 correlate with antiviral humoral responses and distinct immune signatures	96
Oral and Gut Microbial Hubs Associated With Reaction Threshold Interact With Circulating Immune Factors in Peanut Allergy	95
IgG Removal Enhances the Sensitivity of Amoxicillin‐Specific IgE Detection in ImmunoCAP and Radioallergosorbent Test	91
Airway epithelial cell cilia transcriptomic dysregulation is associated with the inflammatory phenotype in asthma	89
Development and validation of the food allergy severity score	86

The second COVID‐19 mRNA vaccine dose enhances the capacity of Spike‐specific memory B cells to bind Omicron BA.2	84
Preclinical Development of GR2002, a Novel Anti‐TSLP Bispecific Antibody With Potent TSLP Inhibitory Effects	82
TOP10‐SCAR: A Global Pharmacovigilance Study on Medications Most Frequently Related to Severe Cutaneous Adverse Reactions	82
Ficolin‐A Protects Against Allergic Asthma via Suppressing ILC2‐Drived Type 2 Inflammation	80
Long‐term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open‐label extension study	77
Persistence of infectious SARS‐CoV‐2 particles for up to 37 days in patients with mild COVID‐19	77
Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies	74
In Memory of Dr. Izabela Kuprys‐Lipinska: A Pioneering Clinician, Scientist, and Beloved Friend	73
The Role of IgE in Crohn's Disease by Impairing the Capacity of Plasmacytoid Dendritic Cells to Generate FOXP3⁺ Tregs	72
25‐hydroxyvitamin D and risk of atopic diseases and infections in early childhood	72
One‐strength dose escalation of house dust mite depot product for subcutaneous immunotherapy is safe and tolerable	71
The impact of exposure to tobacco smoke and e‐cigarettes on asthma‐related outcomes: Systematic review informing the EAACI guidelines on environmental science for allergic diseases and asthma	69
Impact of climate change on atopic dermatitis: A review by the International Eczema Council	68
Shotgun metagenomic sequencing on skin microbiome indicates dysbiosis exists prior to the onset of atopic dermatitis	68
Efficacy and safety of intranasal medications for allergic rhinitis: Network meta‐analysis	67
Intranasal administration of a virus like particles‐based vaccine induces neutralizing antibodies against SARS‐CoV‐2 and variants of concern	67
Core Outcome Set for IgE‐mediated food allergy clinical trials and observational studies of interventions: International Delphi consensus study ‘COMFA’	65
An algorithm for the diagnosis and management of IgE‐mediated food allergy, 2024 update	65
Issue Information ‐ TOC	64
Immunoglobulin E response in health and disease beyond allergic disorders	64
Hot topics in allergen immunotherapy, 2023: Current status and future perspective	64
Issue Information	63
In this Issue: Graphical Abstracts	63
Issue Information	58
What we know and still ignore on COVID‐19 immune pathogenesis and a proposal based on the experience of allergic disorders	58
Evidence of epithelial remodelling but not epithelial–mesenchymal transition by transcriptome profiling in vernal keratoconjunctivitis	57
Allergoid‐mannan conjugates imprint tolerogenic features in human macrophages	56
Mast cell activation is associated with post‐acute COVID‐19 syndrome	56
Immunotherapeutic effects of specific and nonspecific mRNA‐lipid nanoparticles in a mouse model of HDM‐induced airway inflammation	55
Severe and refractory anaphylaxis in pediatric intensive care unit	54